ZA200501133B - Method of treating osteoarthritis - Google Patents

Info

Publication number

ZA200501133B

ZA200501133B ZA200501133A ZA200501133A ZA200501133B ZA 200501133 B ZA200501133 B ZA 200501133B ZA 200501133 A ZA200501133 A ZA 200501133A ZA 200501133 A ZA200501133 A ZA 200501133A ZA 200501133 B ZA200501133 B ZA 200501133B

Authority

ZA

South Africa

Prior art keywords

dimethyl

pain

methyl

substituted

carboxy

Prior art date

2002-08-22

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 261
• 201000008482 osteoarthritis Diseases 0.000 title claims description 61
• 150000001875 compounds Chemical class 0.000 claims description 212
• 150000003839 salts Chemical class 0.000 claims description 147
• SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims description 117
• 150000001983 dialkylethers Chemical class 0.000 claims description 116
• 239000000203 mixture Substances 0.000 claims description 116
• 159000000007 calcium salts Chemical class 0.000 claims description 106
• -1 dialkyl ether compound Chemical class 0.000 claims description 98
• 241000124008 Mammalia Species 0.000 claims description 92
• 208000006820 Arthralgia Diseases 0.000 claims description 82
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 72
• 206010007710 Cartilage injury Diseases 0.000 claims description 68
• ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 claims description 59
• 201000010099 disease Diseases 0.000 claims description 52
• 102000004889 Interleukin-6 Human genes 0.000 claims description 48
• 108090001005 Interleukin-6 Proteins 0.000 claims description 48
• 125000000217 alkyl group Chemical group 0.000 claims description 47
• 230000002917 arthritic effect Effects 0.000 claims description 43
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 43
• 238000011282 treatment Methods 0.000 claims description 43
• 239000003814 drug Substances 0.000 claims description 41
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 39
• 206010003246 arthritis Diseases 0.000 claims description 38
• 230000001684 chronic effect Effects 0.000 claims description 36
• 229960002004 valdecoxib Drugs 0.000 claims description 35
• 230000001154 acute effect Effects 0.000 claims description 34
• 230000003349 osteoarthritic effect Effects 0.000 claims description 33
• 229910052799 carbon Inorganic materials 0.000 claims description 24
• 239000003937 drug carrier Substances 0.000 claims description 23
• 239000003085 diluting agent Substances 0.000 claims description 22
• 230000001404 mediated effect Effects 0.000 claims description 22
• 208000035475 disorder Diseases 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
• 239000000126 substance Substances 0.000 claims description 18
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 125000004432 carbon atom Chemical group C* 0.000 claims description 14
• 125000003342 alkenyl group Chemical group 0.000 claims description 13
• 229940111134 coxibs Drugs 0.000 claims description 13
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 13
• 125000000304 alkynyl group Chemical group 0.000 claims description 12
• 229960000590 celecoxib Drugs 0.000 claims description 12
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 12
• 208000018937 joint inflammation Diseases 0.000 claims description 10
• 229960000371 rofecoxib Drugs 0.000 claims description 9
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
• 230000002757 inflammatory effect Effects 0.000 claims description 8
• 206010040047 Sepsis Diseases 0.000 claims description 6
• ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 claims description 6
• WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims description 6
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims description 6
• 229960004662 parecoxib Drugs 0.000 claims description 6
• 230000009885 systemic effect Effects 0.000 claims description 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
• 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 5
• 125000003545 alkoxy group Chemical group 0.000 claims description 5
• 229960004945 etoricoxib Drugs 0.000 claims description 5
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 5
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
• 229960000994 lumiracoxib Drugs 0.000 claims description 5
• KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims description 5
• 206010025135 lupus erythematosus Diseases 0.000 claims description 5
• 229960003184 carprofen Drugs 0.000 claims description 4
• 229960003314 deracoxib Drugs 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 4
• 125000002837 carbocyclic group Chemical group 0.000 claims description 3
• 150000002148 esters Chemical class 0.000 claims description 3
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
• 150000003536 tetrazoles Chemical class 0.000 claims description 3
• KOWIZHDULJSRPT-WUKNDPDISA-N (3z)-3-[(4-bromophenyl)-(4-methylsulfonylphenyl)methylidene]oxolan-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C=1C=CC(Br)=CC=1)=C/1C(=O)OCC\1 KOWIZHDULJSRPT-WUKNDPDISA-N 0.000 claims description 2
• YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 claims description 2
• HFWZBWTWCKQUCB-RVDMUPIBSA-N 2,6-ditert-butyl-4-[(e)-(2-ethyl-1,1-dioxo-1,2-thiazolidin-5-ylidene)methyl]phenol Chemical compound O=S1(=O)N(CC)CC\C1=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 HFWZBWTWCKQUCB-RVDMUPIBSA-N 0.000 claims description 2
• XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 claims description 2
• NXMZBNYLCVTRGB-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine Chemical compound C1=CC(OCC)=CC=C1C1=NN(N=CC=C2)C2=C1C1=CC=C(S(C)(=O)=O)C=C1 NXMZBNYLCVTRGB-UHFFFAOYSA-N 0.000 claims description 2
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
• 239000011575 calcium Substances 0.000 claims description 2
• 229960001929 meloxicam Drugs 0.000 claims description 2
• 229960000965 nimesulide Drugs 0.000 claims description 2
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 2
• MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
• 229910052791 calcium Inorganic materials 0.000 claims 1
• IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 1
• 208000002193 Pain Diseases 0.000 description 242
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
• 150000003568 thioethers Chemical class 0.000 description 86
• 150000002576 ketones Chemical class 0.000 description 85
• 125000003710 aryl alkyl group Chemical group 0.000 description 81
• 241000700159 Rattus Species 0.000 description 76
• 210000000548 hind-foot Anatomy 0.000 description 59
• 239000007924 injection Substances 0.000 description 59
• 238000002347 injection Methods 0.000 description 59
• 230000003628 erosive effect Effects 0.000 description 57
• 102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 description 49
• 241001465754 Metazoa Species 0.000 description 46
• 230000003405 preventing effect Effects 0.000 description 43
• 210000000845 cartilage Anatomy 0.000 description 42
• 230000005764 inhibitory process Effects 0.000 description 37
• 239000003981 vehicle Substances 0.000 description 37
• 230000000694 effects Effects 0.000 description 36
• 125000000547 substituted alkyl group Chemical group 0.000 description 35
• 239000000243 solution Substances 0.000 description 33
• 230000008859 change Effects 0.000 description 31
• 230000008407 joint function Effects 0.000 description 31
• 238000009472 formulation Methods 0.000 description 27
• 230000002401 inhibitory effect Effects 0.000 description 27
• 239000003826 tablet Substances 0.000 description 26
• 239000002253 acid Substances 0.000 description 25
• 239000003112 inhibitor Substances 0.000 description 24
• 238000010170 biological method Methods 0.000 description 22
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
• 229940079593 drug Drugs 0.000 description 21
• 210000003127 knee Anatomy 0.000 description 21
• 208000024891 symptom Diseases 0.000 description 21
• 241000282414 Homo sapiens Species 0.000 description 20
• 239000000546 pharmaceutical excipient Substances 0.000 description 20
• 208000004454 Hyperalgesia Diseases 0.000 description 19
• 231100000673 dose–response relationship Toxicity 0.000 description 18
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
• 238000012360 testing method Methods 0.000 description 18
• 206010065390 Inflammatory pain Diseases 0.000 description 17
• 239000003795 chemical substances by application Substances 0.000 description 17
• 210000003414 extremity Anatomy 0.000 description 17
• 230000004054 inflammatory process Effects 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 229940124597 therapeutic agent Drugs 0.000 description 17
• 108010008165 Etanercept Proteins 0.000 description 16
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
• 238000004458 analytical method Methods 0.000 description 16
• 208000000094 Chronic Pain Diseases 0.000 description 15
• 206010061218 Inflammation Diseases 0.000 description 15
• 239000002775 capsule Substances 0.000 description 15
• 210000000629 knee joint Anatomy 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• 208000005298 acute pain Diseases 0.000 description 14
• 206010053552 allodynia Diseases 0.000 description 14
• 239000002552 dosage form Substances 0.000 description 14
• 230000001575 pathological effect Effects 0.000 description 14
• 239000011780 sodium chloride Substances 0.000 description 14
• 229920002261 Corn starch Polymers 0.000 description 13
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 13
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 13
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 13
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 13
• 239000008120 corn starch Substances 0.000 description 13
• 229940099112 cornstarch Drugs 0.000 description 13
• 230000006378 damage Effects 0.000 description 13
• 239000012453 solvate Substances 0.000 description 13
• 241000282472 Canis lupus familiaris Species 0.000 description 12
• 206010019233 Headaches Diseases 0.000 description 12
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
• 238000007792 addition Methods 0.000 description 11
• 239000000460 chlorine Substances 0.000 description 11
• 229910052801 chlorine Inorganic materials 0.000 description 11
• 230000003247 decreasing effect Effects 0.000 description 11
• 229910052731 fluorine Inorganic materials 0.000 description 11
• 229960000485 methotrexate Drugs 0.000 description 11
• 125000000753 cycloalkyl group Chemical group 0.000 description 10
• 239000012154 double-distilled water Substances 0.000 description 10
• 239000008187 granular material Substances 0.000 description 10
• 229910052739 hydrogen Inorganic materials 0.000 description 10
• 210000003041 ligament Anatomy 0.000 description 10
• 125000006239 protecting group Chemical group 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
• 208000008035 Back Pain Diseases 0.000 description 9
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 9
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
• 241000283973 Oryctolagus cuniculus Species 0.000 description 9
• 125000005466 alkylenyl group Chemical group 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 125000004429 atom Chemical group 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 229940073621 enbrel Drugs 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 210000002683 foot Anatomy 0.000 description 9
• 231100000869 headache Toxicity 0.000 description 9
• 239000001257 hydrogen Substances 0.000 description 9
• 229960002725 isoflurane Drugs 0.000 description 9
• 239000008101 lactose Substances 0.000 description 9
• 235000019359 magnesium stearate Nutrition 0.000 description 9
• 239000002464 receptor antagonist Substances 0.000 description 9
• 229940044551 receptor antagonist Drugs 0.000 description 9
• 206010005949 Bone cancer Diseases 0.000 description 8
• 208000018084 Bone neoplasm Diseases 0.000 description 8
• 108010037464 Cyclooxygenase 1 Proteins 0.000 description 8
• 208000005171 Dysmenorrhea Diseases 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• 208000001640 Fibromyalgia Diseases 0.000 description 8
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 8
• 229910052794 bromium Inorganic materials 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 238000010171 animal model Methods 0.000 description 7
• 208000037765 diseases and disorders Diseases 0.000 description 7
• 229960000403 etanercept Drugs 0.000 description 7
• 239000007789 gas Substances 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
• 238000001543 one-way ANOVA Methods 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 230000003068 static effect Effects 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• 102100033902 Endothelin-1 Human genes 0.000 description 6
• 101800004490 Endothelin-1 Proteins 0.000 description 6
• 241000282326 Felis catus Species 0.000 description 6
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 6
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
• 230000003110 anti-inflammatory effect Effects 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 230000008355 cartilage degradation Effects 0.000 description 6
• 239000003086 colorant Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 239000002158 endotoxin Substances 0.000 description 6
• 230000002962 histologic effect Effects 0.000 description 6
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 229920006008 lipopolysaccharide Polymers 0.000 description 6
• 231100000252 nontoxic Toxicity 0.000 description 6
• 230000003000 nontoxic effect Effects 0.000 description 6
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
• 210000005065 subchondral bone plate Anatomy 0.000 description 6
• 239000000829 suppository Substances 0.000 description 6
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
• 102000000503 Collagen Type II Human genes 0.000 description 5
• 108010041390 Collagen Type II Proteins 0.000 description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
• 102000003815 Interleukin-11 Human genes 0.000 description 5
• 208000003456 Juvenile Arthritis Diseases 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• AMNPXXIGUOKIPP-UHFFFAOYSA-N [4-(carbamothioylamino)phenyl]thiourea Chemical compound NC(=S)NC1=CC=C(NC(N)=S)C=C1 AMNPXXIGUOKIPP-UHFFFAOYSA-N 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 235000010418 carrageenan Nutrition 0.000 description 5
• 239000000679 carrageenan Substances 0.000 description 5
• 229920001525 carrageenan Polymers 0.000 description 5
• 229940113118 carrageenan Drugs 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 239000000706 filtrate Substances 0.000 description 5
• 150000002431 hydrogen Chemical class 0.000 description 5
• 210000001503 joint Anatomy 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000000454 talc Substances 0.000 description 5
• 229910052623 talc Inorganic materials 0.000 description 5
• 230000036269 ulceration Effects 0.000 description 5
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
• 241000416162 Astragalus gummifer Species 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• 206010013935 Dysmenorrhoea Diseases 0.000 description 4
• 241000283086 Equidae Species 0.000 description 4
• 201000005569 Gout Diseases 0.000 description 4
• 108090000177 Interleukin-11 Proteins 0.000 description 4
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
• 102000004140 Oncostatin M Human genes 0.000 description 4
• 108090000630 Oncostatin M Proteins 0.000 description 4
• 241000700157 Rattus norvegicus Species 0.000 description 4
• 229920001615 Tragacanth Polymers 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 239000000674 adrenergic antagonist Substances 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• 210000001188 articular cartilage Anatomy 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 description 4
• 229960001265 ciclosporin Drugs 0.000 description 4
• 229940110456 cocoa butter Drugs 0.000 description 4
• 235000019868 cocoa butter Nutrition 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 239000012458 free base Substances 0.000 description 4
• 230000002496 gastric effect Effects 0.000 description 4
• 239000007903 gelatin capsule Substances 0.000 description 4
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
• 125000005842 heteroatom Chemical group 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 244000144972 livestock Species 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 229960002009 naproxen Drugs 0.000 description 4
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 229920001592 potato starch Polymers 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 235000010487 tragacanth Nutrition 0.000 description 4
• 239000000196 tragacanth Substances 0.000 description 4
• 229940116362 tragacanth Drugs 0.000 description 4
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
• YTTWDTVYXAEAJA-UHFFFAOYSA-N 2,2-dimethyl-hexanoic acid Chemical compound CCCCC(C)(C)C(O)=O YTTWDTVYXAEAJA-UHFFFAOYSA-N 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 238000011740 C57BL/6 mouse Methods 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• 206010007559 Cardiac failure congestive Diseases 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
• 208000035154 Hyperesthesia Diseases 0.000 description 3
• 108010017521 Interleukin-11 Receptors Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• 241000407429 Maja Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000019695 Migraine disease Diseases 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 101100291239 Rattus norvegicus Mia gene Proteins 0.000 description 3
• 229910020008 S(O) Inorganic materials 0.000 description 3
• 238000000692 Student's t-test Methods 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 229960001138 acetylsalicylic acid Drugs 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 150000008064 anhydrides Chemical class 0.000 description 3
• 208000007474 aortic aneurysm Diseases 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 239000003124 biologic agent Substances 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
• 239000003651 drinking water Substances 0.000 description 3
• 235000020188 drinking water Nutrition 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 125000002541 furyl group Chemical group 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 239000008240 homogeneous mixture Substances 0.000 description 3
• 229920002674 hyaluronan Polymers 0.000 description 3
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
• 229960002591 hydroxyproline Drugs 0.000 description 3
• 206010020718 hyperplasia Diseases 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 229940100601 interleukin-6 Drugs 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 239000011812 mixed powder Substances 0.000 description 3
• 230000000051 modifying effect Effects 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• 125000004076 pyridyl group Chemical group 0.000 description 3
• 238000011552 rat model Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 229940061969 rheumatrex Drugs 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 238000012353 t test Methods 0.000 description 3
• 239000007916 tablet composition Substances 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 210000002303 tibia Anatomy 0.000 description 3
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
• 229940087652 vioxx Drugs 0.000 description 3
• PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
• AXXUJNIHMQQIIP-UHFFFAOYSA-N 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid Chemical compound OC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(O)=O AXXUJNIHMQQIIP-UHFFFAOYSA-N 0.000 description 2
• QRMMMWOSHHVOCJ-UHFFFAOYSA-N 2,2-dimethylheptanoic acid Chemical compound CCCCCC(C)(C)C(O)=O QRMMMWOSHHVOCJ-UHFFFAOYSA-N 0.000 description 2
• QEBQEVMZUWUIKD-UHFFFAOYSA-N 4-(3-carboxy-3-methylbutoxy)-2,2-dimethylbutanoic acid Chemical compound OC(=O)C(C)(C)CCOCCC(C)(C)C(O)=O QEBQEVMZUWUIKD-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 241000283087 Equus Species 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 241000282324 Felis Species 0.000 description 2
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 206010018634 Gouty Arthritis Diseases 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
• 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 2
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 102000004553 Interleukin-11 Receptors Human genes 0.000 description 2
• 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 108010082522 Oncostatin M Receptors Proteins 0.000 description 2
• 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102000008866 Prostaglandin E receptors Human genes 0.000 description 2
• 108010088540 Prostaglandin E receptors Proteins 0.000 description 2
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 229940116731 Uricosuric agent Drugs 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000000048 adrenergic agonist Substances 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 229960003459 allopurinol Drugs 0.000 description 2
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000002456 anti-arthritic effect Effects 0.000 description 2
• 230000000843 anti-fungal effect Effects 0.000 description 2
• 230000003070 anti-hyperalgesia Effects 0.000 description 2
• 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 2
• 230000003276 anti-hypertensive effect Effects 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 230000000842 anti-protozoal effect Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000002255 antigout agent Substances 0.000 description 2
• 229960002708 antigout preparations Drugs 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 229940030600 antihypertensive agent Drugs 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000003904 antiprotozoal agent Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 210000000544 articulatio talocruralis Anatomy 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 229960002529 benzbromarone Drugs 0.000 description 2
• WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
• 229940110331 bextra Drugs 0.000 description 2
• 238000012742 biochemical analysis Methods 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 239000003710 calcium ionophore Substances 0.000 description 2
• NVXIEDHPFHVZTC-UHFFFAOYSA-N calcium;methanol Chemical compound [Ca].OC NVXIEDHPFHVZTC-UHFFFAOYSA-N 0.000 description 2
• 239000002327 cardiovascular agent Substances 0.000 description 2
• 229940125692 cardiovascular agent Drugs 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 229940047495 celebrex Drugs 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 229960001338 colchicine Drugs 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229940051427 deramaxx Drugs 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 238000005837 enolization reaction Methods 0.000 description 2
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 239000008241 heterogeneous mixture Substances 0.000 description 2
• 230000003118 histopathologic effect Effects 0.000 description 2
• 102000046949 human MSC Human genes 0.000 description 2
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
• 229960004171 hydroxychloroquine Drugs 0.000 description 2
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 238000010191 image analysis Methods 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229940074383 interleukin-11 Drugs 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 230000037231 joint health Effects 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
• YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 2
• 229960003058 methotrexate sodium Drugs 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 231100000417 nephrotoxicity Toxicity 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 210000000426 patellar ligament Anatomy 0.000 description 2
• 229960001639 penicillamine Drugs 0.000 description 2
• 235000019271 petrolatum Nutrition 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
• 102000030769 platelet activating factor receptor Human genes 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 208000015768 polyposis Diseases 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 238000000634 powder X-ray diffraction Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
• 229960003081 probenecid Drugs 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 239000002089 prostaglandin antagonist Substances 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 229940116176 remicade Drugs 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
• OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
• 210000004872 soft tissue Anatomy 0.000 description 2
• 239000008347 soybean phospholipid Substances 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
• 229960003329 sulfinpyrazone Drugs 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 201000004595 synovitis Diseases 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 239000002562 thickening agent Substances 0.000 description 2
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 239000003383 uricosuric agent Substances 0.000 description 2
• 229940124549 vasodilator Drugs 0.000 description 2
• 239000003071 vasodilator agent Substances 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• ZLSDDICVPOHWTB-UHFFFAOYSA-N 1,11-dihydroxy-2,10-dimethyl-2,10-diphenylundecan-6-one Chemical compound C=1C=CC=CC=1C(CO)(C)CCCC(=O)CCCC(C)(CO)C1=CC=CC=C1 ZLSDDICVPOHWTB-UHFFFAOYSA-N 0.000 description 1
• HLRBENIHKMCTTL-UHFFFAOYSA-N 1,11-dihydroxy-2,2,10,10-tetramethylundecan-6-one Chemical compound OCC(C)(C)CCCC(=O)CCCC(C)(C)CO HLRBENIHKMCTTL-UHFFFAOYSA-N 0.000 description 1
• YUQSKIKOWNWRQV-UHFFFAOYSA-N 1,13-dihydroxy-2,12-dimethyl-2,12-bis(4-methylphenyl)tridecan-7-one Chemical compound C1=CC(C)=CC=C1C(C)(CO)CCCCC(=O)CCCCC(C)(CO)C1=CC=C(C)C=C1 YUQSKIKOWNWRQV-UHFFFAOYSA-N 0.000 description 1
• HGJKCTNNEWONAW-UHFFFAOYSA-N 1,13-dihydroxy-2,12-dimethyl-2,12-bis[4-(2-methylpropyl)phenyl]tridecan-7-one Chemical compound C1=CC(CC(C)C)=CC=C1C(C)(CO)CCCCC(=O)CCCCC(C)(CO)C1=CC=C(CC(C)C)C=C1 HGJKCTNNEWONAW-UHFFFAOYSA-N 0.000 description 1
• FGTDNJHSEFINNG-UHFFFAOYSA-N 1,13-dihydroxy-2,2,12,12-tetramethyltridecan-7-one Chemical compound OCC(C)(C)CCCCC(=O)CCCCC(C)(C)CO FGTDNJHSEFINNG-UHFFFAOYSA-N 0.000 description 1
• ZYXVVXDWQIKBTP-UHFFFAOYSA-N 1-[4-(5,5-dimethyl-6-oxohexoxy)butyl]cyclopentane-1-carbaldehyde Chemical compound O=CC(C)(C)CCCCOCCCCC1(C=O)CCCC1 ZYXVVXDWQIKBTP-UHFFFAOYSA-N 0.000 description 1
• ADVQSOFXAHZIIC-UHFFFAOYSA-N 1-[4-[4-(1-carboxycyclopropyl)butoxy]butyl]cyclopropane-1-carboxylic acid Chemical compound C1CC1(C(O)=O)CCCCOCCCCC1(C(=O)O)CC1 ADVQSOFXAHZIIC-UHFFFAOYSA-N 0.000 description 1
• UBSCUXIZNTXLFW-UHFFFAOYSA-N 11-(10-benzyl-10-carboxy-11-chloroundecoxy)-2,2-diethylundecanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCCCCCCOCCCCCCCCCC(CCl)(C(O)=O)CC1=CC=CC=C1 UBSCUXIZNTXLFW-UHFFFAOYSA-N 0.000 description 1
• ASFNYCBUJKXFTC-UHFFFAOYSA-N 13-(dimethylamino)-2,2,12,12-tetramethyl-7,13-dioxotridecanoic acid Chemical compound CN(C)C(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(O)=O ASFNYCBUJKXFTC-UHFFFAOYSA-N 0.000 description 1
• WJDKTFQIPMJCGR-UHFFFAOYSA-N 2,12-dimethyl-2,12-bis[4-(2-methylpropyl)phenyl]-7-oxotridecanedioic acid Chemical compound C1=CC(CC(C)C)=CC=C1C(C)(C(O)=O)CCCCC(=O)CCCCC(C)(C(O)=O)C1=CC=C(CC(C)C)C=C1 WJDKTFQIPMJCGR-UHFFFAOYSA-N 0.000 description 1
• NHTFPQHLCFYJIJ-UHFFFAOYSA-N 2,2,12,12-tetramethyl-7,13-dioxo-13-(n-phenylanilino)tridecanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(O)=O)C1=CC=CC=C1 NHTFPQHLCFYJIJ-UHFFFAOYSA-N 0.000 description 1
• FUSSBLIWQHHZOG-UHFFFAOYSA-N 2,2,12,12-tetramethyltridecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCC(C)(C)C(O)=O FUSSBLIWQHHZOG-UHFFFAOYSA-N 0.000 description 1
• LLFXYXPRAJLGTE-UHFFFAOYSA-N 2,2,15,15-tetramethylhexadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCC(C)(C)C(O)=O LLFXYXPRAJLGTE-UHFFFAOYSA-N 0.000 description 1
• OAWLZLONZCDJSJ-UHFFFAOYSA-N 2,2,17,17-tetramethyloctadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(O)=O OAWLZLONZCDJSJ-UHFFFAOYSA-N 0.000 description 1
• DJKWDKJYFYUEBQ-UHFFFAOYSA-N 2,2,9,9-tetramethyldecane-1,10-diol Chemical compound OCC(C)(C)CCCCCCC(C)(C)CO DJKWDKJYFYUEBQ-UHFFFAOYSA-N 0.000 description 1
• LYDQREUUWSXQDS-UHFFFAOYSA-N 2,2,9,9-tetramethyldecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCC(C)(C)C(O)=O LYDQREUUWSXQDS-UHFFFAOYSA-N 0.000 description 1
• NAHQIQHWEZQFAU-UHFFFAOYSA-N 2,2-diethyl-5-(5-methoxy-4,4-dimethyl-5-oxopentoxy)pentanoic acid Chemical compound CCC(CC)(C(O)=O)CCCOCCCC(C)(C)C(=O)OC NAHQIQHWEZQFAU-UHFFFAOYSA-N 0.000 description 1
• VUAXHMVRKOTJKP-UHFFFAOYSA-N 2,2-dimethylbutyric acid Chemical compound CCC(C)(C)C(O)=O VUAXHMVRKOTJKP-UHFFFAOYSA-N 0.000 description 1
• IKNDGHRNXGEHTO-UHFFFAOYSA-N 2,2-dimethyloctanoic acid Chemical compound CCCCCCC(C)(C)C(O)=O IKNDGHRNXGEHTO-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• RIUBYPPHIXWKKB-UHFFFAOYSA-N 2-(3-chloropropyl)-5-(5-formyl-7-hydroxy-5-methylheptoxy)-2-methylpentanoic acid Chemical compound OCCC(C)(C=O)CCCCOCCCC(C)(C(O)=O)CCCCl RIUBYPPHIXWKKB-UHFFFAOYSA-N 0.000 description 1
• YQLYBTRODIEZQI-UHFFFAOYSA-N 2-(bromomethyl)-9-[4-carboxy-4-(chloromethyl)-5-hydroxypentoxy]-2-(iodomethyl)nonanoic acid Chemical compound OCC(CCl)(C(O)=O)CCCOCCCCCCCC(CBr)(CI)C(O)=O YQLYBTRODIEZQI-UHFFFAOYSA-N 0.000 description 1
• XEDWMSUMRFDIOJ-UHFFFAOYSA-N 2-[4-[8-carboxy-9-methoxy-8-(methoxymethyl)nonoxy]butyl]-2-pentylheptanoic acid Chemical compound CCCCCC(CCCCC)(C(O)=O)CCCCOCCCCCCCC(COC)(COC)C(O)=O XEDWMSUMRFDIOJ-UHFFFAOYSA-N 0.000 description 1
• VRSUAEIFUULQBH-UHFFFAOYSA-N 2-[6-[5,5-dimethyl-6-(oxan-2-yloxy)hexyl]sulfanyl-2,2-dimethylhexoxy]oxane Chemical compound C1CCCOC1OCC(C)(C)CCCCSCCCCC(C)(C)COC1CCCCO1 VRSUAEIFUULQBH-UHFFFAOYSA-N 0.000 description 1
• YAPBXDDPSIAEHH-UHFFFAOYSA-N 2-ethyl-2-[2-(5-ethyl-5-methoxycarbonylheptoxy)ethyl]-3-methylbutanoic acid Chemical compound COC(=O)C(CC)(CC)CCCCOCCC(CC)(C(C)C)C(O)=O YAPBXDDPSIAEHH-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• CCPAROICJDHUHE-UHFFFAOYSA-N 3,14-diethyl-3,14-dimethylhexadecanedioic acid Chemical compound OC(=O)CC(C)(CC)CCCCCCCCCCC(C)(CC)CC(O)=O CCPAROICJDHUHE-UHFFFAOYSA-N 0.000 description 1
• SRJWQXGYTPCQBI-UHFFFAOYSA-N 3,3,12,12-tetramethyltetradecanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCC(C)(C)CC(O)=O SRJWQXGYTPCQBI-UHFFFAOYSA-N 0.000 description 1
• MYCWUMRBKGTYGG-UHFFFAOYSA-N 3,3,14,14-tetracyclohexylhexadecanedioic acid Chemical compound C1CCCCC1C(C1CCCCC1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C1CCCCC1)C1CCCCC1 MYCWUMRBKGTYGG-UHFFFAOYSA-N 0.000 description 1
• MNXRNHVTBJYOMC-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-chlorophenyl)hexadecanedioic acid Chemical compound C=1C=C(Cl)C=CC=1C(C=1C=CC(Cl)=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 MNXRNHVTBJYOMC-UHFFFAOYSA-N 0.000 description 1
• WRAJNZCUSWQWRS-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-hydroxyphenyl)hexadecanedioic acid Chemical compound C=1C=C(O)C=CC=1C(C=1C=CC(O)=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 WRAJNZCUSWQWRS-UHFFFAOYSA-N 0.000 description 1
• BCDDMJAZZDQSQD-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-methoxyphenyl)hexadecanedioic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)(CC(O)=O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BCDDMJAZZDQSQD-UHFFFAOYSA-N 0.000 description 1
• HYVCJBOGBXWNLU-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-methylphenyl)hexadecanedioic acid Chemical compound C1=CC(C)=CC=C1C(C=1C=CC(C)=CC=1)(CC(O)=O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 HYVCJBOGBXWNLU-UHFFFAOYSA-N 0.000 description 1
• XJOQLLOLGFBHDP-UHFFFAOYSA-N 3,3,14,14-tetrakis(hydroxymethyl)hexadecanedioic acid Chemical compound OC(=O)CC(CO)(CO)CCCCCCCCCCC(CO)(CO)CC(O)=O XJOQLLOLGFBHDP-UHFFFAOYSA-N 0.000 description 1
• DTGWPBXWEDHULN-UHFFFAOYSA-N 3,3,14,14-tetrakis(prop-2-enyl)hexadecanedioic acid Chemical compound OC(=O)CC(CC=C)(CC=C)CCCCCCCCCCC(CC=C)(CC=C)CC(O)=O DTGWPBXWEDHULN-UHFFFAOYSA-N 0.000 description 1
• GORDJQZOFOVSQR-UHFFFAOYSA-N 3,3,14,14-tetramethylhexadec-8-enedioic acid Chemical compound OC(=O)CC(C)(C)CCCCC=CCCCCC(C)(C)CC(O)=O GORDJQZOFOVSQR-UHFFFAOYSA-N 0.000 description 1
• LWFCJLGMDXFDJL-UHFFFAOYSA-N 3,3,14,14-tetramethylhexadecanediamide Chemical compound NC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(N)=O LWFCJLGMDXFDJL-UHFFFAOYSA-N 0.000 description 1
• ZHNHHDJUKFLIMS-UHFFFAOYSA-N 3,3,14,14-tetraphenylhexadecanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 ZHNHHDJUKFLIMS-UHFFFAOYSA-N 0.000 description 1
• ALPCCMYAJZAWAO-UHFFFAOYSA-N 3,3,16,16-tetramethyloctadecanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCCCC(C)(C)CC(O)=O ALPCCMYAJZAWAO-UHFFFAOYSA-N 0.000 description 1
• RQKGSIGQBVSOAD-UHFFFAOYSA-N 3,3,18,18-tetramethylicosanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCCCCCC(C)(C)CC(O)=O RQKGSIGQBVSOAD-UHFFFAOYSA-N 0.000 description 1
• KEPKSKRXODHWGP-UHFFFAOYSA-N 3-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound CCCC(C(C)(C)C(O)=O)OCCCCC(C)(C)C(O)=O KEPKSKRXODHWGP-UHFFFAOYSA-N 0.000 description 1
• HGXXYAGULYAJKN-UHFFFAOYSA-N 3-[3-[3-(2-carboxy-2-methylpropyl)benzoyl]phenyl]-2,2-dimethylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=CC=CC(C(=O)C=2C=C(CC(C)(C)C(O)=O)C=CC=2)=C1 HGXXYAGULYAJKN-UHFFFAOYSA-N 0.000 description 1
• FTBNTXVJGPCPPJ-UHFFFAOYSA-N 5-(3-carboxy-3-methylbutoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOCCC(C)(C)C(O)=O FTBNTXVJGPCPPJ-UHFFFAOYSA-N 0.000 description 1
• NIYWONCEAOSHIM-UHFFFAOYSA-N 5-(4-carboxy-4-methylpentoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOCCCC(C)(C)C(O)=O NIYWONCEAOSHIM-UHFFFAOYSA-N 0.000 description 1
• JWUQKQJBJGXVQR-UHFFFAOYSA-N 5-(5-hydroxy-4-methyl-4-phenylpentyl)sulfanyl-2-methyl-2-phenylpentan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCSCCCC(C)(CO)C1=CC=CC=C1 JWUQKQJBJGXVQR-UHFFFAOYSA-N 0.000 description 1
• JSOCMLGSQVOMQK-UHFFFAOYSA-N 5-(5-hydroxy-4-methyl-4-phenylpentyl)sulfinyl-2-methyl-2-phenylpentan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCS(=O)CCCC(C)(CO)C1=CC=CC=C1 JSOCMLGSQVOMQK-UHFFFAOYSA-N 0.000 description 1
• ROHIGTBTCFMSNZ-UHFFFAOYSA-N 5-[(4-carboxy-4-methylpentyl)sulfanylmethylsulfanyl]-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCSCSCCCC(C)(C)C(O)=O ROHIGTBTCFMSNZ-UHFFFAOYSA-N 0.000 description 1
• ZBEHQYBIKITXIF-UHFFFAOYSA-N 5-[2-(4-carboxy-4-methylpentyl)sulfanylethylsulfanyl]-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCSCCSCCCC(C)(C)C(O)=O ZBEHQYBIKITXIF-UHFFFAOYSA-N 0.000 description 1
• MGNOFERDBFZQEP-UHFFFAOYSA-N 5-[2-(5-hydroxy-4,4-dimethylpentoxy)ethoxy]-2,2-dimethylpentan-1-ol Chemical compound OCC(C)(C)CCCOCCOCCCC(C)(C)CO MGNOFERDBFZQEP-UHFFFAOYSA-N 0.000 description 1
• SGAOHSSCGUPUAO-UHFFFAOYSA-N 5-[3-ethyl-11-[6-ethyl-6-(2h-tetrazol-5-yl)octoxy]undecan-3-yl]-2h-tetrazole Chemical compound N=1N=NNC=1C(CC)(CC)CCCCCCCCOCCCCCC(CC)(CC)C1=NN=NN1 SGAOHSSCGUPUAO-UHFFFAOYSA-N 0.000 description 1
• ZLZUXDUGPRKMRG-UHFFFAOYSA-N 5-[4-(4-carboxy-3,3-dimethylbutyl)sulfanylbutylsulfanyl]-3,3-dimethylpentanoic acid Chemical compound OC(=O)CC(C)(C)CCSCCCCSCCC(C)(C)CC(O)=O ZLZUXDUGPRKMRG-UHFFFAOYSA-N 0.000 description 1
• NPRXDJJJMKMIAK-UHFFFAOYSA-N 6,11-dioxo-3,3,14,14-tetraphenylhexadecanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC(=O)O)CCC(=O)CCCCC(=O)CCC(CC(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 NPRXDJJJMKMIAK-UHFFFAOYSA-N 0.000 description 1
• AZEOCZDDNNNLII-UHFFFAOYSA-N 6-(5-butyl-5-methoxycarbonylnonoxy)-2-ethyl-2-methylhexanoic acid Chemical compound CCCCC(CCCC)(C(=O)OC)CCCCOCCCCC(C)(CC)C(O)=O AZEOCZDDNNNLII-UHFFFAOYSA-N 0.000 description 1
• QNIHXFBGHLJFBJ-UHFFFAOYSA-N 6-(5-carboxy-5-ethylheptoxy)-2,2-diethylhexanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCOCCCCC(CC)(CC)C(O)=O QNIHXFBGHLJFBJ-UHFFFAOYSA-N 0.000 description 1
• CQMGKZDPSUYHTH-UHFFFAOYSA-N 6-(5-carboxy-5-phenylhexyl)sulfanyl-2-methyl-2-phenylhexanoic acid Chemical compound C=1C=CC=CC=1C(C)(C(O)=O)CCCCSCCCCC(C)(C(O)=O)C1=CC=CC=C1 CQMGKZDPSUYHTH-UHFFFAOYSA-N 0.000 description 1
• FTJKEUBBWSIOEH-UHFFFAOYSA-N 6-(5-hydroxy-5-methylhexoxy)-2-methylhexan-2-ol Chemical compound CC(C)(O)CCCCOCCCCC(C)(C)O FTJKEUBBWSIOEH-UHFFFAOYSA-N 0.000 description 1
• XWZKWLJMXQMPKY-UHFFFAOYSA-N 6-(6-ethyl-6-formyloctoxy)-2,2-dimethylhexanoic acid Chemical compound CCC(CC)(C=O)CCCCCOCCCCC(C)(C)C(O)=O XWZKWLJMXQMPKY-UHFFFAOYSA-N 0.000 description 1
• ULDZFCNXQRYRSI-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexoxy)-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCOCCCCC(C)(C)CO ULDZFCNXQRYRSI-UHFFFAOYSA-N 0.000 description 1
• AXKNHRFGQOGVFD-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexyl)sulfanyl-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCSCCCCC(C)(C)CO AXKNHRFGQOGVFD-UHFFFAOYSA-N 0.000 description 1
• OFBPTQHRYOEMOZ-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexyl)sulfinyl-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCS(=O)CCCCC(C)(C)CO OFBPTQHRYOEMOZ-UHFFFAOYSA-N 0.000 description 1
• CABKSVMDTCABIY-UHFFFAOYSA-N 6-(6-hydroxy-5-methyl-5-phenylhexyl)sulfanyl-2-methyl-2-phenylhexan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCCSCCCCC(C)(CO)C1=CC=CC=C1 CABKSVMDTCABIY-UHFFFAOYSA-N 0.000 description 1
• OUDQFSIFGNXYLD-UHFFFAOYSA-N 6-(6-hydroxy-5-methyl-5-phenylhexyl)sulfinyl-2-methyl-2-phenylhexan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCCS(=O)CCCCC(C)(CO)C1=CC=CC=C1 OUDQFSIFGNXYLD-UHFFFAOYSA-N 0.000 description 1
• CHBCZBPNDMEOEL-UHFFFAOYSA-N 7-(4-carboxy-4-methylpentoxy)-2,2-dimethylheptanoic acid Chemical compound OC(=O)C(C)(C)CCCCCOCCCC(C)(C)C(O)=O CHBCZBPNDMEOEL-UHFFFAOYSA-N 0.000 description 1
• FRJUMZKUZWELAL-UHFFFAOYSA-N 7-(5-carboxy-5-ethyl-6-methylheptoxy)-2-ethyl-2-(2-methylpropyl)heptanoic acid Chemical compound CC(C)CC(C(O)=O)(CC)CCCCCOCCCCC(CC)(C(C)C)C(O)=O FRJUMZKUZWELAL-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• SCYSJZSCOPJXEE-UHFFFAOYSA-N 8-(4-carboxy-4-methylpentoxy)-2,2-diethyloctanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCCCOCCCC(C)(C)C(O)=O SCYSJZSCOPJXEE-UHFFFAOYSA-N 0.000 description 1
• HZKWZWPUKXZEEW-UHFFFAOYSA-N 9-hydroxy-3-(6-hydroxy-5,5-dimethylhexyl)-8,8-dimethylnonan-2-one Chemical compound OCC(C)(C)CCCCC(C(=O)C)CCCCC(C)(C)CO HZKWZWPUKXZEEW-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 229940124810 Alzheimer's drug Drugs 0.000 description 1
• 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 206010060968 Arthritis infective Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 241000283705 Capra hircus Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 229910052684 Cerium Inorganic materials 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• 241000224483 Coccidia Species 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 208000033131 Congenital factor II deficiency Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 208000028006 Corneal injury Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 102100029109 Endothelin-3 Human genes 0.000 description 1
• 108010072844 Endothelin-3 Proteins 0.000 description 1
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 241000282323 Felidae Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• QQHJDPROMQRDLA-UHFFFAOYSA-N Hexadecane-1,16-dioic acid Natural products OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 206010022714 Intestinal ulcer Diseases 0.000 description 1
• 206010023230 Joint stiffness Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 229940122048 Leucotriene receptor antagonist Drugs 0.000 description 1
• 206010024453 Ligament sprain Diseases 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• HYSMCRNFENOHJH-UHFFFAOYSA-N MEDICA 16 Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(O)=O HYSMCRNFENOHJH-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 206010050031 Muscle strain Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028836 Neck pain Diseases 0.000 description 1
• 101100221725 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-17 gene Proteins 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
• 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000008558 Osteophyte Diseases 0.000 description 1
• 241000283898 Ovis Species 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 101150050331 PGIC gene Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 229920005439 Perspex® Polymers 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 208000004550 Postoperative Pain Diseases 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
• 206010036600 Premature labour Diseases 0.000 description 1
• RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000606651 Rickettsiales Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 241000282890 Sus Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 239000000219 Sympatholytic Substances 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 241000219161 Theobroma Species 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006374 Uterine Cervicitis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 108010003059 aggrecanase Proteins 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• ZRYCZAWRXHAAPZ-UHFFFAOYSA-N alpha,alpha-dimethyl valeric acid Chemical compound CCCC(C)(C)C(O)=O ZRYCZAWRXHAAPZ-UHFFFAOYSA-N 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229940035674 anesthetics Drugs 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
• 230000007131 anti Alzheimer effect Effects 0.000 description 1
• 230000003367 anti-collagen effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940035678 anti-parkinson drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 230000000386 athletic effect Effects 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 230000000599 auto-anti-genic effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229960001671 azapropazone Drugs 0.000 description 1
• WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 229910052790 beryllium Inorganic materials 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 206010008323 cervicitis Diseases 0.000 description 1
• ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 230000002508 compound effect Effects 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000002089 crippling effect Effects 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 150000004292 cyclic ethers Chemical class 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• PXNICCQYLXPRIW-UHFFFAOYSA-N dibenzyl [5-[4-bis(phenylmethoxy)phosphoryloxy-4-methylpentoxy]-2-methylpentan-2-yl] phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCC=1C=CC=CC=1)OC(C)(C)CCCOCCCC(C)(C)OP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 PXNICCQYLXPRIW-UHFFFAOYSA-N 0.000 description 1
• QXUGBFZAJYXWAO-UHFFFAOYSA-N dibenzyl [6-[5-bis(phenylmethoxy)phosphoryloxy-5-methylhexoxy]-2-methylhexan-2-yl] phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCC=1C=CC=CC=1)OC(C)(C)CCCCOCCCCC(C)(C)OP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 QXUGBFZAJYXWAO-UHFFFAOYSA-N 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• LLCNSWNSEHNQFE-UHFFFAOYSA-N diethyl 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioate Chemical compound CCOC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(=O)OCC LLCNSWNSEHNQFE-UHFFFAOYSA-N 0.000 description 1
• YMIGBZCDNMUJIH-UHFFFAOYSA-N diethyl 2,2,12,12-tetramethyl-7-oxotridecanedioate Chemical compound CCOC(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(=O)OCC YMIGBZCDNMUJIH-UHFFFAOYSA-N 0.000 description 1
• MAVBJYZRJVMJSF-UHFFFAOYSA-N diethyl 3,3,14,14-tetramethylhexadecanedioate Chemical compound CCOC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(=O)OCC MAVBJYZRJVMJSF-UHFFFAOYSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• MSTYEGBNWBXKEH-UHFFFAOYSA-N dimethyl 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioate Chemical compound COC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(=O)OC MSTYEGBNWBXKEH-UHFFFAOYSA-N 0.000 description 1
• ZEQBTPAAGXVVFA-UHFFFAOYSA-N dimethyl 2,15-dichloro-3,3,14,14-tetramethylhexadecanedioate Chemical compound COC(=O)C(Cl)C(C)(C)CCCCCCCCCCC(C)(C)C(Cl)C(=O)OC ZEQBTPAAGXVVFA-UHFFFAOYSA-N 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• KJDNTLXQVUSDEG-UHFFFAOYSA-L disodium [2-methyl-5-(4-methyl-4-phosphonooxypentoxy)pentan-2-yl] phosphate Chemical compound [Na+].CC(CCCOCCCC(C)(OP(=O)(O)O)C)(C)OP([O-])([O-])=O.[Na+] KJDNTLXQVUSDEG-UHFFFAOYSA-L 0.000 description 1
• UNOLHKIYEHQTNF-UHFFFAOYSA-L disodium [2-methyl-6-(5-methyl-5-phosphonooxyhexoxy)hexan-2-yl] phosphate Chemical compound [Na+].CC(CCCCOCCCCC(C)(OP(=O)(O)O)C)(C)OP([O-])([O-])=O.[Na+] UNOLHKIYEHQTNF-UHFFFAOYSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000002792 enkephalinase inhibitor Substances 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• HIQMPLFRKJIMLD-UHFFFAOYSA-N ethyl 11-(6-hexoxy-5,5-dimethyl-6-oxohexoxy)-2,2-dimethylundecanoate Chemical compound CCCCCCOC(=O)C(C)(C)CCCCOCCCCCCCCCC(C)(C)C(=O)OCC HIQMPLFRKJIMLD-UHFFFAOYSA-N 0.000 description 1
• CJEQNDYMODCRLG-UHFFFAOYSA-N ethyl 2,2-dimethyl-5-sulfanylpentanoate Chemical compound CCOC(=O)C(C)(C)CCCS CJEQNDYMODCRLG-UHFFFAOYSA-N 0.000 description 1
• CYGYYRHOCJKRIH-UHFFFAOYSA-N ethyl 5-(5-ethoxy-4,4-dimethyl-5-oxopentoxy)-2,2-dimethylpentanoate Chemical compound CCOC(=O)C(C)(C)CCCOCCCC(C)(C)C(=O)OCC CYGYYRHOCJKRIH-UHFFFAOYSA-N 0.000 description 1
• RDPATGHAVQEVBJ-UHFFFAOYSA-N ethyl 6-(6-ethoxy-5,5-dimethyl-6-oxohexoxy)-2,2-dimethylhexanoate Chemical compound CCOC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(=O)OCC RDPATGHAVQEVBJ-UHFFFAOYSA-N 0.000 description 1
• UVWSLXZTGTXBCT-UHFFFAOYSA-N ethyl 6-[6-ethoxy-5,5-bis(hydroxymethyl)-6-oxohexoxy]-2,2-bis(hydroxymethyl)hexanoate Chemical compound CCOC(=O)C(CO)(CO)CCCCOCCCCC(CO)(CO)C(=O)OCC UVWSLXZTGTXBCT-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
• 239000001761 ethyl methyl cellulose Substances 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
• 230000002178 gastroprotective effect Effects 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 102000054766 genetic haplotypes Human genes 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 239000003324 growth hormone secretagogue Substances 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 238000010231 histologic analysis Methods 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 229940018991 hyalgan Drugs 0.000 description 1
• 229960002474 hydralazine Drugs 0.000 description 1
• 125000001183 hydrocarbyl group Chemical group 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
• 229960002367 lasofoxifene Drugs 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 229940096405 magnesium cation Drugs 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
• 230000005499 meniscus Effects 0.000 description 1
• 230000002175 menstrual effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
• VYKFUWZZYAUUJN-UHFFFAOYSA-N methyl 8-(8-methoxy-7,7-dimethyl-8-oxooctoxy)-2,2-dimethyloctanoate Chemical compound COC(=O)C(C)(C)CCCCCCOCCCCCCC(C)(C)C(=O)OC VYKFUWZZYAUUJN-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229940101972 mirapex Drugs 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 230000019261 negative regulation of glycolysis Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
• 229960001597 nifedipine Drugs 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• 239000012740 non-selective inhibitor Substances 0.000 description 1
• 230000001777 nootropic effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 229960001289 prazosin Drugs 0.000 description 1
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
• 208000026440 premature labor Diseases 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
• 150000004672 propanoic acids Chemical class 0.000 description 1
• 229960002934 propentofylline Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 201000007183 prothrombin deficiency Diseases 0.000 description 1
• 239000000612 proton pump inhibitor Substances 0.000 description 1
• 229940126409 proton pump inhibitor Drugs 0.000 description 1
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
• 229960000245 rasagiline Drugs 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000006894 reductive elimination reaction Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 239000002461 renin inhibitor Substances 0.000 description 1
• 229940086526 renin-inhibitors Drugs 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 229940113775 requip Drugs 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 229940099315 rimadyl Drugs 0.000 description 1
• 238000006798 ring closing metathesis reaction Methods 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 230000005808 skin problem Effects 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 229940036220 synvisc Drugs 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229940000238 tasmar Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BXMYVNSHJNBFIO-UHFFFAOYSA-N tetraethyl 2,2,11,11-tetramethyldodecane-1,1,12,12-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC BXMYVNSHJNBFIO-UHFFFAOYSA-N 0.000 description 1
• GCHZOPYORPQCIX-UHFFFAOYSA-N tetraethyl 2,2,13,13-tetramethyltetradecane-1,1,14,14-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC GCHZOPYORPQCIX-UHFFFAOYSA-N 0.000 description 1
• GIQMITBANDPQQH-UHFFFAOYSA-N tetraethyl 2,2,17,17-tetramethyloctadecane-1,1,18,18-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC GIQMITBANDPQQH-UHFFFAOYSA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229940098465 tincture Drugs 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 125000004665 trialkylsilyl group Chemical group 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1